Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
poot_buttagina
poot_buttagina Mar. 12 at 11:08 PM
$MREO I thought this might be interesting to anyone who didn't know already. This will make my work easier and help keep some a little more honest.
0 · Reply
poot_buttagina
poot_buttagina Mar. 12 at 11:06 PM
$MREO A significant regulatory change is coming on March 18, 2026. Under the "Holding Foreign Insiders Accountable Act," all Mereo directors and officers will be required to file Form 3, 4, and 5 reports moving forward. This will provide unprecedented transparency into their daily trading activity starting next week. The End of the "Foreign Loophole" Historically, directors and officers of foreign companies listed in the US (like Mereo, which is based in the UK) were exempt from Section 16 of the Exchange Act. The Old Way: If a Mereo director bought or sold shares, they only had to report it to the UK's Financial Conduct Authority (FCA). US investors often had to go hunting through foreign filings to find out what was happening. The New Way (March 18, 2026): The SEC is forcing foreign insiders to use the same Form 3, 4, and 5 system as US companies like Apple or Tesla.
0 · Reply
poot_buttagina
poot_buttagina Mar. 12 at 11:04 PM
$MREO Form 3 Initial Ownership: The first time an insider tells the SEC exactly how many shares they own. This is the "Audit." We will see exactly how much "skin in the game" every single director has right now. Form 4 Changes in Ownership: Must be filed within 2 business days of any buy or sell. No more "secret" selling. If a director dumps shares following a conference, you'll know in 48 hours. Form 5 Annual Wrap-up: Small transactions or gifts that weren't reported on a Form 4. Catches anything that might have slipped through the cracks during the year.
0 · Reply
Cajo_79_Silva
Cajo_79_Silva Mar. 12 at 1:20 PM
$MREO https://www.linkedin.com/posts/mereo-biopharma_last-week-wills-hughes-wilson-represented-activity-7437793407739105280-CAcS?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAUAUAkBgNKfEucLfDqygpe_z5nxWKSiGpc
0 · Reply
PennyGod1759
PennyGod1759 Mar. 12 at 12:19 PM
$MREO ✅✅✅✅✅
0 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 10:18 PM
$MREO Alvelestat: Denise Scots-Knight’s Direct Commentary Denise Scots-Knight (CEO of MREO) was clear about the company's financial discipline regarding their lead owned asset. Moving Forward: The program is "Phase 3 ready," but they are not going to fund it alone. The Quote (Verified Baseline): > "Our primary focus for alvelestat remains on our ongoing partnering discussions. We have a robust Phase 3 design that has been aligned with both the FDA and EMA... but to execute a global pivotal study of this scale, we are prioritizing a strategic collaboration." The Takeaway: She confirmed they are preserving their $41M cash runway (which lasts into mid-2027) by refusing to start the Phase 3 solo. They are actively pitching the program to "Big Pharma" partners during this week's 1-on-1 sessions.
2 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 10:18 PM
$MREO The Intent: Management (specifically Eric Crombez, CMO of RARE) stated that the company is moving toward a Type C meeting with the FDA. The Quote (Verified Baseline): > "We are looking at the totality of the data... the goal is to discuss with the FDA the use of Bone Mineral Density (BMD) as a surrogate endpoint for accelerated approval. The biological signal in the younger Cosmic cohort [ages 2-7] is consistent with what we’ve seen in older patients." Tactical Nuance: They are emphasizing that the "fracture rate was unexpectedly low in the placebo group," which mathematically prevented them from hitting the primary goal. They are banking on the 2-7 age group sub-data (the "Cosmic" study) to prove clinical benefit to the FDA.
0 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 4:10 PM
$MREO So later i will post some quotes from RARE on where they are as far as asking for a type c meeting to move forward with resubmission. Also, Denise simply regurgitated the same thing said for two years "seeking a partner or funding for Alvelestat" and continues to be true. My theory was that the position they are in is make or break for the company going forward. At this point of feet dragging it sounds like a type c meeting will not be asked for until this summer, and obviously nobody wants to touch alvelestat or it would not still be sitting there as dead weight. I was wrong to think that a r/s was out of the question as that now seems the only viable option to get back in accordance. I will still update all positive and negative news moving forward to keep you informed.
1 · Reply
YakingBio
YakingBio Mar. 11 at 4:48 AM
$MREO dead money sell
0 · Reply
alphabetsop
alphabetsop Mar. 10 at 2:05 PM
$MREO i am sure a direction will be had for setrusumab. alvelestat is a joke….3 years and still no deal. Denisse and that pos from pds bio are the two most incompetent ceos in bioland
1 · Reply
Latest News on MREO
Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs


poot_buttagina
poot_buttagina Mar. 12 at 11:08 PM
$MREO I thought this might be interesting to anyone who didn't know already. This will make my work easier and help keep some a little more honest.
0 · Reply
poot_buttagina
poot_buttagina Mar. 12 at 11:06 PM
$MREO A significant regulatory change is coming on March 18, 2026. Under the "Holding Foreign Insiders Accountable Act," all Mereo directors and officers will be required to file Form 3, 4, and 5 reports moving forward. This will provide unprecedented transparency into their daily trading activity starting next week. The End of the "Foreign Loophole" Historically, directors and officers of foreign companies listed in the US (like Mereo, which is based in the UK) were exempt from Section 16 of the Exchange Act. The Old Way: If a Mereo director bought or sold shares, they only had to report it to the UK's Financial Conduct Authority (FCA). US investors often had to go hunting through foreign filings to find out what was happening. The New Way (March 18, 2026): The SEC is forcing foreign insiders to use the same Form 3, 4, and 5 system as US companies like Apple or Tesla.
0 · Reply
poot_buttagina
poot_buttagina Mar. 12 at 11:04 PM
$MREO Form 3 Initial Ownership: The first time an insider tells the SEC exactly how many shares they own. This is the "Audit." We will see exactly how much "skin in the game" every single director has right now. Form 4 Changes in Ownership: Must be filed within 2 business days of any buy or sell. No more "secret" selling. If a director dumps shares following a conference, you'll know in 48 hours. Form 5 Annual Wrap-up: Small transactions or gifts that weren't reported on a Form 4. Catches anything that might have slipped through the cracks during the year.
0 · Reply
Cajo_79_Silva
Cajo_79_Silva Mar. 12 at 1:20 PM
$MREO https://www.linkedin.com/posts/mereo-biopharma_last-week-wills-hughes-wilson-represented-activity-7437793407739105280-CAcS?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAUAUAkBgNKfEucLfDqygpe_z5nxWKSiGpc
0 · Reply
PennyGod1759
PennyGod1759 Mar. 12 at 12:19 PM
$MREO ✅✅✅✅✅
0 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 10:18 PM
$MREO Alvelestat: Denise Scots-Knight’s Direct Commentary Denise Scots-Knight (CEO of MREO) was clear about the company's financial discipline regarding their lead owned asset. Moving Forward: The program is "Phase 3 ready," but they are not going to fund it alone. The Quote (Verified Baseline): > "Our primary focus for alvelestat remains on our ongoing partnering discussions. We have a robust Phase 3 design that has been aligned with both the FDA and EMA... but to execute a global pivotal study of this scale, we are prioritizing a strategic collaboration." The Takeaway: She confirmed they are preserving their $41M cash runway (which lasts into mid-2027) by refusing to start the Phase 3 solo. They are actively pitching the program to "Big Pharma" partners during this week's 1-on-1 sessions.
2 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 10:18 PM
$MREO The Intent: Management (specifically Eric Crombez, CMO of RARE) stated that the company is moving toward a Type C meeting with the FDA. The Quote (Verified Baseline): > "We are looking at the totality of the data... the goal is to discuss with the FDA the use of Bone Mineral Density (BMD) as a surrogate endpoint for accelerated approval. The biological signal in the younger Cosmic cohort [ages 2-7] is consistent with what we’ve seen in older patients." Tactical Nuance: They are emphasizing that the "fracture rate was unexpectedly low in the placebo group," which mathematically prevented them from hitting the primary goal. They are banking on the 2-7 age group sub-data (the "Cosmic" study) to prove clinical benefit to the FDA.
0 · Reply
poot_buttagina
poot_buttagina Mar. 11 at 4:10 PM
$MREO So later i will post some quotes from RARE on where they are as far as asking for a type c meeting to move forward with resubmission. Also, Denise simply regurgitated the same thing said for two years "seeking a partner or funding for Alvelestat" and continues to be true. My theory was that the position they are in is make or break for the company going forward. At this point of feet dragging it sounds like a type c meeting will not be asked for until this summer, and obviously nobody wants to touch alvelestat or it would not still be sitting there as dead weight. I was wrong to think that a r/s was out of the question as that now seems the only viable option to get back in accordance. I will still update all positive and negative news moving forward to keep you informed.
1 · Reply
YakingBio
YakingBio Mar. 11 at 4:48 AM
$MREO dead money sell
0 · Reply
alphabetsop
alphabetsop Mar. 10 at 2:05 PM
$MREO i am sure a direction will be had for setrusumab. alvelestat is a joke….3 years and still no deal. Denisse and that pos from pds bio are the two most incompetent ceos in bioland
1 · Reply
LDT79
LDT79 Mar. 10 at 12:16 PM
$MREO where the fuck is Rubric - did all these tutes screw us over?
0 · Reply
SaySomethingNice
SaySomethingNice Mar. 10 at 11:40 AM
0 · Reply
Bgirl_smirk
Bgirl_smirk Mar. 9 at 9:50 AM
$MREO it’s ready long term hold I like it
1 · Reply
poot_buttagina
poot_buttagina Mar. 7 at 9:52 PM
$MREO So with no PR on any presentation for next week from MREO, but we do have PR from RARE who will be presenting BMD results and their intentions on a path forward....does that mean Rare has taken the full lead or might we be in the room for the presentation? I guess time will tell. Here is what i have so far👇
1 · Reply
poot_buttagina
poot_buttagina Mar. 7 at 9:52 PM
$MREO MREO "Stealth" Presence (Leerink & Barclays) While MREO has not yet listed a public webcast, the following signals confirm their active presence on the ground: Registration Portals: MREO is currently appearing in the investor registration dropdowns for both conferences, which is used by institutional "Whales" to book private 1-on-1 breakout sessions. Management Attendance: CEO Dr. Denise Scots-Knight is expected to lead these private sessions, focusing on the "totality of data" strategy for setrusumab and the upcoming Phase 3 milestones for alvelestat.
0 · Reply
DarkSonar
DarkSonar Mar. 6 at 11:20 PM
$MREO Too bad, I feel is setting up nicely. 🔬
1 · Reply
DarkSonar
DarkSonar Mar. 6 at 11:17 PM
$MREO I was looking at this again for a possible future trade but now is going through a lawsuit too!! And apparently all these Institutional money coming in two months ago now turned away in a -38%… Well, that put a stop to wanting to buy this in the area as the daily chart is looking good. 🔬
1 · Reply
Svetli_stock
Svetli_stock Mar. 4 at 7:11 PM
$MREO 9.03.26 - 0.5$-0.7$
2 · Reply
Magnificient
Magnificient Mar. 4 at 3:56 PM
$MREO any catalyst neat term
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 11:42 PM
$MREO RSI: 50.00, MACD: -0.0717 Vol: 0.02, MA20: 0.40, MA50: 0.66 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SebNo1234
SebNo1234 Mar. 3 at 7:15 PM
0 · Reply
DarkSonar
DarkSonar Mar. 3 at 4:41 PM
$MREO It’s holding this price range nicely though. Maybe time to swing it but will need new DD since I bet lots changed in the last couple of months. 🔬
0 · Reply